Chargement en cours...
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
ABP 980 was developed as a biosimilar to trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), that is indicated for the treatment of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer. ABP 980 is approved in the U...
Enregistré dans:
| Publié dans: | Target Oncol |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer International Publishing
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6875516/ https://ncbi.nlm.nih.gov/pubmed/31620980 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-019-00675-z |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|